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Abstract
Objective: Our aim was to determine the frequency of skeletal metastasis in germ cell tumours (GCT) at baseline and 
relapse on conventional technetium-99m methylene diphosphonate (Tc-99m MDP) whole body bone scan (bone scan) 
and to evaluate the effect of bone metastases on survival.
Materials and Methods: Electronic medical records of histologically proven GCT over 64 months were retrospectively 
analysed. Basic demographic and histologic information were correlated with the presence of osseous and visceral 
metastases. 5-year disease-free survival (DFS) and overall survival (OS) were calculated in presence, the absence of 
bone metastases at baseline and at relapse.
Results: A total of 130 gonadal and extragonadal GCT patients underwent Tc-99m MDP bone scans; four with 
insufficient data were excluded from the study. 47% were females and 53% were males with the age range of 
1 month – 72 years. 105 (83%) were under 18 years of age. Osseous metastasis was detected in 12 (9.5%). Two 
(17%) had solitary and 10 (83%) had multifocal skeletal metastases. Clinically, 83% had localised bone pain. Osseous 
metastases were more frequently associated with mixed GCT and yolk sac tumour. 50% of mediastinal GCT developed 
bone metastases. 42% died within 4–18 months. There was a statistically significant impact of visceral metastases on 
DFS and OS. OS at 5 years in patients without bone metastases, with bone metastases at baseline and bone metastases 
at relapse, was 77%, 38% and 75%, respectively. 5-year DFS for the same cohort groups was 63%, 38% and 20%, 
respectively.
Conclusion: Osseous involvement was found in 9.5% of GCT patients undergoing diagnostic Tc-99m MDP bone 
scan. Baseline skeletal evaluation for metastases should be done, particularly in the case of bone pains or known 
systemic metastases. Although skeletal relapses are rare, they have a grim outcome.
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Introduction
Germ cell tumours (GCTs) are one of the most common 
malignant tumours, comprising 1% of all the solid tumours 
in young male adults.[1] GCT usually metastasizes to 
retroperitoneal lymph nodes. Osseous metastases are 
a rare entity, particularly at primary diagnosis and its 
true incidence remains unknown. It is usually a late 
manifestation, with synchronous haematogenous spread to 
the lung, liver, and brain and the overall prognosis of bone 
involvement is as poor as hepatic or central nervous system 
(CNS) metastases.[2] Moreover, non-pulmonary metastases 
are considered poor prognosticators. For patients with 
metastatic GCT, prognostic factors at primary diagnosis 
are well recognised and the international germ cell cancer 
consensus cooperative group (IGCCCG) guidelines 
are followed to determine treatment regimens for 
chemotherapy. Bone metastases classify the patient into 
high-risk (HR) (non seminomatous) group or intermediate 
risk (IR) (seminomatous) group.[3]
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Conventional Technetium-99m methylene diphosphonate 
(Tc-99m MDP) whole body bone scan (bone scan), 
computerised tomography (CT), and magnetic resonance 
imaging (MRI) are various modalities for diagnosing 
bone metastases as indicated.[4] The incidence of osseous 
involvement, its responsiveness to chemotherapy and 
long-term prognosis remain poorly defined.[5]
Objective
The main objectives of this study were as follows:
1. To determine the frequency of skeletal metastases in 
patients with newly diagnosed GCT and/or relapsed 
after first-line chemotherapy.1.
2. To explore the characteristics, potential risk factors 
for skeletal metastases and overall and disease-free 
survival (DFS) after chemotherapy in patients with 
and without bone metastases.
Materials and Methods
Electronic medical records of 130 consecutive patients 
treated at our institution for histologically proven 
gonadal or extragonadal GCT between October 2010 
and February 2016 were retrospectively analysed. All 
patients underwent Tc-99m MDP bone scan as part 
of staging workup, or when relapse was suspected 
following initial high-dose chemotherapy. Where 
suspicious, the osseous uptake on Tc-99m MDP bone 
scan was further correlated with additional radiological 
imaging.
The association of bone metastases was assessed with 
gender, age, histopathology, stage and risk stratification 
according to International Germ Cell Consensus 
Classification guidelines formulated in 1997,[3] tumour 
marker elevation including lactate dehydrogenase/
LDH (Normal = 240–480 IU/L), alpha-fetoprotein/AFP 
(cutoff 10kU/L), and human chorionic gonadotropins/Β-
HCG (cutoff 2 U/L). Overall survival (OS), DFS and 
treatment response were evaluated in patients with bone 
metastases at baseline and relapse and compared to those 
without metastases and those with non-osseous, visceral 
metastases.
Imaging
Baseline Tc-99m MDP planar whole body bone scans 
were acquired 2.5 h after the intravenous administration 
of Tc-99m MDP. Since 2013, a SPECT/CT scan was 
also acquired to better specify the cause of uptake 
if needed. The scans were reported by experienced 
nuclear physicians. Bone involvement was diagnosed by 
radioisotope uptake. Foci of uptake were confirmed by 
one or more radiological imaging modality including plain 
radiograph, CT scan, MRI scan or 18F-FDG PET-CT as 
indicated clinically.
HR and IR GCT were further evaluated for concurrent 
systemic metastasis. Chemotherapy was administered 
according to UKCCSG GCIII (Extracranial GCT 
guidelines January 2011-Phase III Trial) protocol.
The Institutional Review Board approved the study.
Statistical analysis
All the relevant statistical data were entered into SPSS 
software version. 20 (IBM, USA). Continuous variables 
were presented as mean or median with ranges. Categorical 
variables were presented as absolute and relevant 
frequencies. The correlative analysis was performed using 
the Chi-square or Log-rank test (categorical variables). 
P < 0.05 was considered statistically significant. Survival 
rates were analysed using the method of Kaplan–Meier 
(Kaplan and Meier 1958).
Results
A total of 130 GCT patients underwent Tc-99m MDP bone 
scan between October 2010 and February 2016. Four were 
excluded due to incomplete information. Of the remaining 
126, 59 (47%) were females and 67 (53%) were males. 
Mean age was 18 years (range: 1 month – 72 years). 
105 (83%) were of paediatric age group (under 18 years) 
at the time of initial diagnosis. Patient characteristics are 
summarised in Table 1.
Characteristics of patients with bone metastases
Overall, 9.5% (12/126) had bone metastases either at 
primary diagnosis or relapse. While classifying by the 
IGCCC guidelines, four (33%) had IR and eight (67%) 
had HR GCT.
Of the 12 with bone metastases; five (42%) had mixed 
GCT, three (25%) yolk sac tumour, two (17%) immature 
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teratoma and one each of seminoma (8%) and non-
seminomatous GCT (8%). Tumour markers elevation of 
either LDH or AFP (α−fetoprotein) was seen in 92%. All 
the 12 were non β-HCG secreting tumours.
Bone metastases were found at diagnosis in seven and 
five at relapse. A most frequent site of bone metastases 
was thoracolumbar spine (58%) with cord compression in 







bone metastases n=80 (%)
Age range (years) 1 month–72 years 1–29 1 month–54 years
Male/Female ratio 1:1 2:1 1:1
Site of primary
Gonadal (ovary/testes) 73 (58) 5 (42) 55 (68.8)
Mediastinal 6 (5) 3 (25) 3 (3.7)
Sacrococcygeal 12 (10) 2 (17) 7 (8.8)
Abdominopelvic 22 (17) 2 (17) 15 (18.7)
Others 13 (10) 0 (0) 0 (0)
Histology
Yolk sac tumour 41 (33) 3 (25) 33 (41)
Mixed GCT 34 (27) 5 (42) 22 (27.7)
Seminoma/Germinoma 23 (18) 1 (8) 14 (17.5)
Malignant teratoma 23 (18) 2 (17) 8 (10%)
Non seminomatous GCT 3 (2.4) 1 (8) 1 (1.3)
Embryonal carcinoma 2 (1.6) 0 (0.0) 2 (2.5)
Tumour markers elevation
AFP 74 (59) 8 (67) 56 (70)
Β‑HCG 7 (5.5) 0 (0) 7 (8.7)
LDH 27 (21.4) 6 (50) 18 (22.5)
Non‑osseous metastatic sites
Nodal 55 (44) 8 (67) 47 (59)
Lung 26 (21) 4 (33) 22 (27.5)
Liver 13 (10.2) 1 (8.3) 12 (15)
CNS 1 (0.8) 0 (0.0) 1 (1.3)
IGCCC at initial diagnosis
Low 34 (27) 0 (0.0) 0 (0.0)
Intermediate 52 (41) 4 (33) 48 (60)
High 40 (32) 8 (67) 32 (40)
Response to first‑line chemotherapy 
CR/NED* 55 (43) 0 (0.0) 21 (26)
CR/SD** with no relapse 36 (29) 3 (25) 33 (40)
CR/SD after treating relapse 14 (11) 4 (33) 10 (12.5)
PD*** 21 (17) 5 (42) 16 (21)
Disease free interval (months)
Median (range) 21 (3–62) 22 (4–52) 23 (3–60+)
*Complete response/no evidence of disease, **Complete response/radiologically stable disease, ***Progressive disease. GCT: Germ cell 
tumours, IR/HR: Intermediate risk/High risk, AFP: Alpha‑fetoprotein, Β‑HCG: β‑Human chorionic gonadotropins, LDH: Lactate dehydrogenase, 
CNS: Central nervous system, IGCCC: International germ cell cancer consensus cooperative
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and long bones in 42%. Bone metastases were solitary in 
17% and multifocal in 83%. Clinically, 83% of patients 
were symptomatic with localised bone pains.
In the seven with osseous metastases at baseline, additional 
sites of metastases included; lymph nodes (n = 4), lung 
(n = 2) and liver (n = 1). In five with bone metastases at 
relapse, concomitant metastatic sites were lymph node 
(n = 4), lung (n = 4) and liver (n = 1).
Table 2 outlines the risk category, treatment and outcome 
of patients with bone metastases.
Tc-99m MDP bone scan findings were confirmed by CT 
scan in eight, MRI in six and radiograph in two. An MRI 
scan was used for assessing cord compression in four.
Treatment and outcome of patients with bone metastases
Nearly 42% of patients with bone metastases received 
only first-line chemotherapy, while 33% with progressive 
disease and relapse received additional second-line and 
25% third-line chemotherapies. Table 2 outlines the 
chemotherapy regimens used and the outcome of patients 
with bone metastases.
There was no significant correlation between the presence 
of bone metastases at diagnosis and the subsequent lines 
of chemotherapy received. Response assessment after 
chemotherapy showed stable disease in 33%, partial 
response with the primary irresectable disease in 25% and 
progressive disease in 42%. One with partial response was 
lost to follow-up. A neurological compromise was seen in 
the form of cord compression in four. In these patients, 
palliative management was done with lumbar spine 
radiation therapy (XRT) in one and laminectomy in another.
Five had irresectable primary tumours; two mediastinal 
and three sacrococcygeal/pelvic. XRT was given to three 
primary tumour sites. Based on the last clinical follow-up, 
five died due to progressive disease (median survival – 
9 months; range: 4–18 months); five had no evidence of 
disease after first-line chemotherapy, one required second-
line chemotherapy due to disease relapse and one was lost 
to follow-up. Out of five who died, four had bone metastases 
at primary diagnosis with concurrent nodal and pulmonary 
metastases. One developed bone metastases at relapse 
but had no concurrent visceral metastases. One with bone 
metastases at relapse was lost to follow-up during third-line 
chemotherapy. 50% remained stable with a median follow-
up duration of 29 months (Range: 17–52 months). Survival 
plots according to Kaplan–Meier are presented in Figures 1-5.
Table 2: Chemotherapy regimens, IGCCC‑defined risk and outcome in GCT patient with bone metastases
Patient Chemotherapyregimen IGCCC‑defined risk Outcome
Bone metastases at baseline staging
1 1,2* High Died due to disease
2 1, 2, 3 High Died due to disease
3 1 High Alive
4 1, 2 High Died due to disease
5 1 Intermediate Alive
6 1 High Alive
7 1, 2 High Died due to disease
Bone metastases at relapse
1 1, 2, 3 High Lost to follow‑up
2 1 Intermediate Alive
3 1,2 Intermediate Alive
4 1,2,3 High Died due to disease
5 1 Intermediate Alive
*1. First‑line chemotherapy: Four cycles of BEP (Bleomycin, Etoposide and Cisplatin) in adults and 4–6 cycles of JEB (Carboplatin, Etoposide 
and Bleomycin) in paediatric patients, 2: Second‑line chemotherapy: VeIP (Vinblastine, Ifosfamide and Carboplatin), 3: Third‑line chemothera‑
py: Gemcitabine and Oxaliplatin. IGCCC: International germ cell cancer consensus cooperative, GCT: Germ cell tumours
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Characteristics of patients without bone metastases
Nearly 94% had no bone metastases at baseline. Out of 
these, 30% had low-risk (LR)/Stage I disease, 42% IR 
and 28% HR disease. Details of histological breakup and 
tumour marker status of the 80 with IR and HR without 
bone metastases are shown in Table 1.
Nearly 24% of patients had irresectable primary tumour 
site. Synchronous retroperitoneal/mediastinal nodal, 
Figure 1: Kaplan–Meier curve displaying the 5-year disease-
free survival in intermediate risk and high-risk germ cell 
tumours (No bone metastases, 63%; bone metastases at baseline, 
38% and bone metastases at relapse, 20%). The log-rank test 
showed a statistically significant difference in percent survival 
of patients with and without bone metastases both at baseline 
or relapse
Figure 2: Kaplan–Meier curve showing the 5-year overall 
survival in intermediate risk and high-risk germ cell tumours 
(No bone metastases, 77%; bone metastases at baseline, 38% 
and bone metastases at relapse, 75%). The log-rank test showed 
a statistically significant difference in percent survival of patients 
with and without metastases at baseline (P = 0.02)
Figure 3: Kaplan–Meier curve showing the 5-year disease-free 
survival in intermediate risk and high-risk germ cell tumours 
in relation to visceral metastases other than bone involvement 
(No metastases, 67%; only lung metastases, 71%; only liver 
metastases, 29%; lung + liver metastases, 40% and central 
nervous system involvement, 0%). The log-rank test showed a 
statistically significant difference in percent survival of patients 
with and without visceral metastases (P = 0.0001)
Figure 4: Kaplan–Meier curve showing the 5-year disease-free 
survival of germ cell tumours in relation to international germ 
cell cancer consensus cooperative defined risk assessment 
(intermediate risk [IR], 67% and high risk [HR], 53%). The log-
rank test showed a statistically significant difference in percent 
survival of patients with IR versus HR (P = 0.02)
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pulmonary, hepatic and CNS metastases were seen in 59%, 
27.5%, 15% and 1%, respectively at baseline staging.
Treatment and outcome of patients without bone 
metastases
All Stage I/LR was treated with complete resection of 
primary tumour only or followed by a few cycles of 
systemic chemotherapy with subsequent surveillance with 
tumour markers. At the end of follow-up, all were alive 
and disease free.
Of 80 with IR or HR, 70% were treated with only first-line 
chemotherapy while the rest received either second- or 
third-line chemotherapy due to progressive disease. 
XRT was given to four irresectable primary mediastinal/
abdominal tumours, two with para-aortic nodal masses 
and one with brain metastases.
About 32.5% had disease relapse, out of which 16 had 
progressive disease, rest remained in remission. Seven 
(9%) were lost to follow-up.
13 died with a median OS of 13 months (Range: 
3–29 months); of these two died due to bleomycin toxicity. 
The remaining 59% remained progression free with a 
median OS of 21 months (range: 6–60+months). Ten 
with relapse remained in remission with a median OS of 
28 months (range: 11–60 months).
DFS and OS of patients with and without metastases
Comparing those with bone metastases to those without 
metastases, the following correlations were found:
By spearman’s two-tailed test, patients with bone metastases 
had an equal chance of presenting with visceral (lung, liver 
or both) metastases and various histologic subtypes, as the 
difference was not statistically significant (P = 0.06).
On bivariate analysis, tumour histology (P = 0.02), site of 
primary tumour (P < 0.0001), the risk group (p = 0.02), 
tumour resectibility status (P < 0.001), presence of 
bone metastases at baseline (P < 0.0001) and visceral 
involvement at baseline (P < 0.0001) had significant 
influence on DFS and OS. Survival plots according to 
Kaplan–Meier curves are presented in Figures 1-5.
The 5-year OS in the absence of bone metastases, with 
bone metastases at baseline and bone metastases at 
relapse, was 77%, 38% and 75%, respectively. The 5-year 
DFS for the same cohort groups is 63%, 38% and 20%, 
respectively.
Discussion
Bone metastasis is a rare event in GCT, detected in 5% of 
patients at primary diagnosis.[3] Based on current treatment 
guidelines, the outcome of non-osseous metastatic GCT 
is good, achieving an overall cure rate of over 80% 
after standard chemotherapy. However, a patient with 
osseous metastases achieves 5-year survival rate in the 
range of 45–55% after cisplatin-based combination 
chemotherapy.[5,6] Although bone metastases are rare in 
GCT, prompt and accurate diagnosis are very crucial since 
there is a significant treatment failure rate after first-line 
chemotherapy. Osseous metastases mainly affect young 
males and lead to morbidity in the form of pain and cord 
compression, necessitating the use of radiotherapy in 
chemoresistant cases.[7]
In routine practice, screening of bone metastases is 
generally not endorsed in adult cases of GCT. Patients 
do not always present with bony symptoms related to 
metastases; they are usually detected incidentally on 
Figure 5: Kaplan–Meier curve showing the 5-year disease-free 
survival of intermediate risk high-risk germ cell tumours in 
relation to resectibility of primary tumour site (irresectable, 22% 
and respectable, 76%). The log-rank test showed a statistically 
significant difference in percent survival of patients with 
resectable versus irresectable disease (P = 0.0001)
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imaging. Jamal-Hanjani et al.[2] found incidental bone 
metastases in 58%.
In our study, 83% of symptomatic patients had osseous 
metastases on Tc-99m MDP bone scans. Studies have 
suggested that back pain can be a manifestation of para-
aortic lymphadenopathy;[8] however, consideration should 
always be given to metastatic disease especially if bone 
tenderness is present.
Hitchins et al.[5] reported 3% incidence of bone metastases 
in gonadal and extragonadal GCT at primary diagnosis 
and 9% at relapse with concomitant retroperitoneal 
and pulmonary metastases in all. Oechsle et al.[9] found 
primary bone metastases in 40/434 (9%) patients, with 
frequent histology of primary mediastinal tumours, 
yolk sac and synchronous liver metastases. In our study, 
50% of non-seminomatous mediastinal GCT had bone 
metastases. In addition, 67% had retroperitoneal nodal 
diseases, 33% had synchronous lung metastases and 8.3% 
had lung and liver metastases, suggesting simultaneous 
lymphatic and haematological spread. Tumour markers 
elevation was more frequently seen in the presence of 
bone metastases (92%) as compared to the rest of the study 
population (79%). Bokemeyer et al.[10] concluded that non-
seminomatous histology, mediastinal primary site, presence 
of non-pulmonary visceral metastases or marked elevation 
of serum tumour markers are poor prognosticators. In 
another study by Mead et al.[11] found a 3-year survival 
rate of 68% in 33% of patients with raised markers (either 
AFP>1000 kU/L or β-HCG >10,000 IU/L) among other 
poor prognostic factors versus 93% survival rate in 67% 
without raised markers. However, in our study none of the 
patients with bone metastases had HCG secreting features.
Relapse in patients with primary bone metastases is less 
common than failure of cisplatin-based chemotherapy 
leading to progressive disease. In our study, five patients 
with bone metastases died due to progressive disease 
<1 year after diagnosis. The 5-year OS of patients with 
bone disease at relapse was significantly better; 75% 
versus 38% in primary bone metastases.
In our study, three patients had isolated bone metastases 
without synchronous nodal/visceral metastases, out of 
which one was a case of testicular seminoma rarely 
reported in literature.[4,12-14]
Seven patients with bone metastases did not respond 
to cisplatin-based chemotherapy and were switched to 
second- and third-line regimens with radiotherapy to 
local disease sites. In addition to progression in bone 
metastases, relapse with new-onset lung metastases in 
three and liver disease in one patient was seen. Two of 
these patients had isolated skeletal metastases at baseline 
with no extraskeletal disease. By the end of follow-up, 
five died despite salvage treatment with a median survival 
of 9 months, one was stable with an irresectable primary 
pelvic mass and one was lost to follow-up. Hence, the 
optimal treatment approach to bone metastases in patients 
with bone metastases remains elusive.
Limitations of this study are primarily related to the fact 
that data were gathered retrospectively. However, since 
bone metastases in GCT are not frequent, prospective 
data collection would not be easy. We were able to reach 
meaningful outcomes from this data set. Our hospital did 
not have a SPECT/CT scanner before September 2013; 
therefore, only planar scintigraphy was acquired before 
that and correlative radiologic imaging was performed 
separately where needed.
There were some variations in protocols over the course of 
this study. Since 2013, all patients underwent Tc-99m MDP 
bone scan, before that although most had bone scintigraphy, 
some who did not were excluded from this study.
Conclusion
Skeletal metastases were found in 9.5% of GCT patients, 
7.6% at baseline staging and 5.4% at relapse in IR or HR 
GCT. Based on our findings, baseline skeletal evaluation for 
metastases; especially in the presence of bone pain or known 
systemic metastases should be done because although skeletal 
relapses are rare, they have a dismal outcome. IGCCCG 
defined risk stratification, primary tumour resectability and 
visceral metastases are a better predictors of survival.
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